TransCode Therapeutics, Inc.
RNAZ
$10.26
$0.848.92%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.00M | 5.38M | 5.95M | 5.23M | 6.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.65M | 15.54M | 15.66M | 14.67M | 17.81M |
| Operating Income | -14.65M | -15.54M | -15.66M | -14.67M | -17.81M |
| Income Before Tax | -24.60M | -25.51M | -16.76M | -14.93M | -17.91M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.60 | -25.51 | -16.76 | -14.93 | -17.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.60M | -25.51M | -16.76M | -14.93M | -17.91M |
| EBIT | -14.65M | -15.54M | -15.66M | -14.67M | -17.81M |
| EBITDA | -14.60M | -15.47M | -15.57M | -14.55M | -17.68M |
| EPS Basic | -492.92 | -487.79 | -417.64 | -146.06 | -- |
| Normalized Basic EPS | -308.09 | -304.89 | -261.04 | -91.29 | -- |
| EPS Diluted | -492.92 | -487.79 | -417.64 | -146.06 | -- |
| Normalized Diluted EPS | -308.09 | -304.89 | -261.04 | -91.29 | -- |
| Average Basic Shares Outstanding | 1.04M | 210.00K | 37.70K | 15.90K | -- |
| Average Diluted Shares Outstanding | 1.04M | 210.00K | 37.70K | 15.90K | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |